An observational study in Interstitial Lung Disease, Sarcoidosis and Idiopathic Pulmonary Fibrosis, sponsored by University of Kansas Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-10.
Sponsored by University of Kansas Medical Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 201 studies in Lung Diseases, Interstitial with a site in United States — 67 open to participants now, 83 under way, 19 of them phase 3. Lung Diseases, Interstitial · United States.
Among the 201 studies in Lung Diseases, Interstitial with a site in United States, this one is the 20th largest by planned enrollment of the 60 observational ones that give a count, is one of 17 that started in 2021, is one of 61 observational ones, reaches primary completion later than 78 of the 82 other live ones, and was the 127th registered.
681 studies on the registry are indexed under Lung Diseases, Interstitial; 245 are open to participants now.
Browse Lung Diseases, Interstitial studies →67 of the 201 studies in Lung Diseases, Interstitial with a site in United States are open now. Recruiting first, the newest first:
Insmed Incorporated · Sites in United States
Ages 18–85
Tectonic Operating Company, Inc. · Sites in United States, Poland, Romania and 3 more countries
Ages 18–80
University of California, San Francisco · Sites in United States
Ages 18+
NS Pharma, Inc. · Sites in United States, Japan
Ages 18–80
National Heart, Lung, and Blood Institute (NHLBI) · Sites in United States
Ages 18–100
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 172 Lung Diseases, Interstitial studies recruiting now, 108 (63%) set no upper age limit and 25 (15%) stop at 75 or younger; 13 take children under 18; 21 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
201 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 61 · Phase 3 37 · Phase 4 5
First in 1999; this study’s year is marked. 17 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000 is above the median of 157 across 278 observational studies indexed under Lung Diseases, Interstitial.
Median enrollment 53 across the 138 interventional studies, 327 across the 60 observational. Of the 105 that completed or were terminated, 51 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
79 of 201 have an industry lead sponsor. The 10 most frequent:
University of Kansas Medical Center is the lead sponsor of 492 studies on the registry; 110 are open to participants now.
Of its 38 completed or terminated interventional studies of FDA-regulated products, 24 (63%) have results posted.
University of Kansas Medical Center has 1 study filed under Lung Diseases, Interstitial — fewer than ten, so there is no comparison to draw.
25 of the studies in Lung Diseases, Interstitial with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05925803Phase 3AstraZenecaDetermine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY) | 2027-01-06 |
| NCT06806592Phase 3Boehringer IngelheimA Study to Test Whether Nerandomilast Helps People With Lung Fibrosis Related to Rheumatic Diseases | 2027-04-15 |
| NCT05943535Phase 3United TherapeuticsStudy of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) | 2027-11 |
| NCT06195072Scleroderma Research Foundation, Inc.Platform Clinical Study for Conquering Scleroderma | 2026-11 |
| NCT07333183Pulmovant, Inc.A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD | 2026-12 |
Add all 25 to your calendar (.ics) → With an account.
Among the 201 studies in Lung Diseases, Interstitial with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Establish a interstitial lung disease (ILD) registry and biorepository to lead towards a further understanding of the disease.
The University of Kansas ILD and Rare Lung Disease clinic sees hundreds of new patients per year. The investigators would like to leverage this resource to develop an Interstitial Lung Disease Research Unit (ILDRU) repository and database to help develop new methods for early diagnosis, uncover underlying genetic and environmental risk factors, as well as potential treatment targets in the broad range of interstitial lung diseases and rare lung diseases (RLD).
Patients with ILD, RLD and subjects at risk for ILD
Inclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Collect clinically obtained data for patients with ILD, RLD and risk for ILD/RLD to support research.
Time frame: Enrollment to Year 10
Establish a collection of biological samples from patients with ILD, RLD and subjects at risk for ILD.
Time frame: Enrollment to Year 10
Correlate biological samples with individual longitudinal clinical data.
Time frame: Enrollment to Year 10
Provide biological samples to researchers performing studies in ILD and RLD.
Time frame: Enrollment to Year 10
Collect historical data and imaging from deceased patients with ILD.
Time frame: Enrollment to Year 10
Plan to share: Yes — Contact Kimberly Lovell to discuss accessing IPD
No publications or documents are linked to this record.
Started Aug 2021 (actual). Primary completion is estimated for Aug 2031, 119 months after the start.
Of 111 non-industry observational studies under Lung Diseases, Interstitial, half reached primary completion within 72 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 274. This study's planned 119 months is above that.
Counting every sponsor, half of 132 studies reached it within 55 months; a quarter within 31 and three quarters within 83.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Kansas Medical Center →